Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of G3041 vs SEVIKAR in Healthy Volunteers
NCT02058472Phase 1Unknown
- Sponsor
- Dong-A Pharmaceutical
- Start
- Dec 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of amlodipine + olmesartan medoxomil in hypertension (HTN) (2 arms), sponsored by Dong-A Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.
02
Drugs
amlodipine + olmesartan medoxomil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02058472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058472.